Jennifer Sorrell, MD

  • Jennifer Lauren Sorrell



Trabajo y Educación

Formación Profesional

Temple University School of Medicine Registrar, Philadelphia, PA, 5/19/2005


McGaw Medical Center of Northwestern University, Chicago, IL, 6/30/2008

McGaw Medical Center of Northwestern University, Chicago, IL, 6/30/2014


Columbia University Medical Center Anesthesiology Training, New York, NY, 6/30/2015

Certificaciones Médicas

Dermatology, American Board of Dermatology

Pediatric Dermatology, American Board of Dermatology

Pediatrics, American Board of Pediatrics



Todo Publicaciones

Use of Transparent Film Dressing for Dermoscopy of Mucosal Lesions PEDIATRIC DERMATOLOGY Sorrell, J., Lauren, C. T. 2016; 33 (1): 106-107

View details for DOI 10.1111/pde.12661

View details for Web of Science ID 000373066300035

Eruptive Xanthomas Masquerading as Molluscum Contagiosum PEDIATRICS Sorrell, J., Salvaggio, H., Garg, A., Guo, L., Duck, S. C., Paller, A. S. 2014; 134 (1): E257-E260


Eruptive xanthomas are cutaneous manifestations of hyperlipidemias in which lipids accumulate in large foam cells within the skin. They classically present as crops of 1- to 4-mm yellow-orange papules and are often associated with extreme hypertriglyceridemia. We describe a 12-year-old boy with autism who was thought to have widespread molluscum contagiosum for a year before dermatologic consultation was obtained. Recognition of eruptive xanthomas led to the discovery of massive hypertriglyceridemia (serum triglycerides 6853 mg/dL) and diabetes mellitus. Through medical intervention, including insulin and fenofibrate therapy, and dietary modification with weight loss, the xanthomas cleared during the subsequent months, and his serum triglyceride levels nearly normalized.

View details for DOI 10.1542/peds.2013-2108

View details for Web of Science ID 000338774800031

View details for PubMedID 24918225

Life-threatening dermatologic adverse events in oncology ANTI-CANCER DRUGS Rosen, A. C., Balagula, Y., Raisch, D. W., Garg, V., Nardone, B., Larsen, N., Sorrell, J., West, D. P., Anadkat, M. J., Lacouture, M. E. 2014; 25 (2): 225-234


The incidences of life-threatening toxicities such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are inconsistently reported. The potential association of anticancer agents with SJS or TEN has not been systematically investigated. We searched the literature (Ovid: 1950 to June 2013 and PubMed: 1948 to June 2013) using terms for SJS/TEN and anticancer therapies. Primary case reports, case series, and clinical trials were included. In addition, MedWatch, the Food and Drug Administration Adverse Event Reporting System (FAERS), was searched (1968 to August 2012) for SJS/TEN reports associated with anticancer therapies. Proportional reporting ratios (PRR>2, N>3), empirical Bayes geometric mean (EBGM>2, N>3), and lower 95% confidence interval (EBGM0.05>2) were used as thresholds to constitute a signal of association between SJS/TEN and anticancer drugs. There were 46 SJS and 37 TEN cases associated with 18 and 22 anticancer drugs in the literature, respectively. Among cases in the FAERS, significant signals were associated with SJS for bendamustine and with TEN for bendamustine, busulfan, chlorambucil, fludarabine, lomustine, and procarbazine. Several drugs reported in the published literature to be associated with SJS/TEN were not found to have significant signals in FAERS. Proactive pharmacovigilance to detect and define safety signals serves to aid oncology practitioners in the recognition of possible, yet uncommon, serious, and/or life-threatening skin reactions.

View details for DOI 10.1097/CAD.0000000000000032

View details for Web of Science ID 000329876400012

View details for PubMedID 24108082

Topical Timolol 0.5% Gel-Forming Solution for Small Deep Facial Infantile Hemangiomas PEDIATRIC DERMATOLOGY Sorrell, J., Chamlin, S. L. 2013; 30 (5): 592-594


We report three cases of successful treatment of proliferating deep infantile hemangiomas with topical timolol 0.5% gel-forming solution (GFS) used two to three times daily. We recommend considering timolol as an initial option for small, deep facial hemangiomas that are not causing functional compromise or complications but may have an unsatisfactory cosmetic appearance. In our experience, albeit limited, this is a safe alternative to watchful waiting.

View details for DOI 10.1111/pde.12209

View details for Web of Science ID 000324092500030

View details for PubMedID 23889228

Dermatoscopic evolution of dysplastic nevi showing high-grade dysplasia in a metastatic melanoma patient on vemurafenib JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Gerami, P., Sorrell, J., Martini, M. 2012; 67 (6): E275-E276

View details for DOI 10.1016/j.jaad.2012.05.031

View details for Web of Science ID 000312131200016

View details for PubMedID 23158636

Update in Molecular Diagnostics in Melanocytic Neoplasms ADVANCES IN ANATOMIC PATHOLOGY Cooper, C., Sorrell, J., Gerami, P. 2012; 19 (6): 410-416


Future classification systems for melanocytic neoplasms will likely include the integration of molecular aberrations. A number of studies have shown that many gene mutations and chromosomal copy number aberrations may correlate with characteristic clinical and morphologic features for melanocytic neoplasms. This review discusses newly described familial germline mutations such as the BRCA1-associated protein-1 familial melanoma syndrome, recently described somatic mutations, and chromosomal copy number aberrations recently described in melanoma. Further, we discuss how these specific molecular aberrations correlate with specific clinical and morphologic features in melanocytic neoplasm and their implications for prognosis and molecular diagnostics. In addition, we discuss state of the art advancements in molecular diagnostics for melanocytic neoplasms and newly developed fluorescence in situ hybridization assays including the utility of fluorescence in situ hybridization for 9p21 in spitzoid melanocytic neoplasms. Lastly, we discuss a phenomenon known as paradoxical activation of wild-type BRAF seen in patients treated with vemurafenib and some potential clinical presentations of this process.

View details for DOI 10.1097/PAP.0b013e318271a5cb

View details for Web of Science ID 000309968400006

View details for PubMedID 23060066

Pathogenesis-Based Therapy Reverses Cutaneous Abnormalities in an Inherited Disorder of Distal Cholesterol Metabolism JOURNAL OF INVESTIGATIVE DERMATOLOGY Paller, A. S., van Steensel, M. A., Rodriguez-Martin, M., Sorrell, J., Heath, C., Crumrine, D., van Geel, M., Noda Cabrera, A., Elias, P. M. 2011; 131 (11): 2242-2248


Identification of the underlying genetic, cellular, and biochemical basis of lipid metabolic disorders provides an opportunity to deploy corrective, mechanism-targeted, topical therapy. We assessed this therapeutic approach in two patients with Congenital Hemidysplasia with Ichthyosiform erythroderma and Limb Defects (CHILD) syndrome, an X-linked dominant disorder of distal cholesterol metabolism. On the basis of the putative pathogenic role of both pathway-product deficiency of cholesterol and accumulation of toxic metabolic intermediates, we assessed the efficacy of combined therapy with lovastatin and cholesterol. We also evaluated the basis for the poorly understood, unique lateralization of the cutaneous and bone malformations of CHILD syndrome by analyzing gene activation in abnormal and unaffected skin. Ultrastructural analysis of affected skin showed evidence of both cholesterol depletion and toxic metabolic accumulation. Topical treatment with lovastatin/cholesterol (but not cholesterol alone) virtually cleared skin lesions by 3 months, accompanied by histological and ultrastructural normalization of epidermal structure and lipid secretion. The unusual lateralization of abnormalities in CHILD syndrome reflects selective clearance of keratinocytes and fibroblasts that express the mutant allele from the unaffected side. These findings validate pathogenesis-based therapy that provides the deficient end product and prevents accumulation of toxic metabolites, an approach of potential utility for other syndromic lipid metabolic disorders.

View details for DOI 10.1038/jid.2011.189

View details for Web of Science ID 000296240100018

View details for PubMedID 21753784

Oral Sucrose for Pain Relief in Young Infants with Hemangiomas Treated with Intralesional Steroids PEDIATRIC DERMATOLOGY Sorrell, J., Carmichael, C., Chamlin, S. 2010; 27 (2): 154-155


Intralesional corticosteroids are one preferred method for treating small localized infantile hemangiomas because of efficacy in halting proliferation and minimal systemic side effects. Although often efficacious, this procedure is uncomfortable for infants. We describe the successful use of an oral 24% sucrose solution given via needleless syringe to the anterior tip of the tongue or in combination with a pacifier as an analgesic during intralesional injection of infantile hemangioma. Options for anesthesia in this young age group include topical prilocaine/lidocaine, injectable lidocaine, and parent soothing. Most often, topical or intralesional anesthesia is deferred when treating hemangiomas of infancy with intralesional corticosteroids. We use oral sucrose as a compassionate option.

View details for DOI 10.1111/j.1525-1470.2010.01120.x

View details for Web of Science ID 000276949400007

View details for PubMedID 20537065

A 7-day-old Boy with a Congenital Vascular Nodule PEDIATRIC ANNALS Sorrell, J., Chamlin, S. L. 2010; 39 (2): 63-65

View details for DOI 10.3928/00904481-20100120-04

View details for Web of Science ID 000274638200004

View details for PubMedID 20166633